• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用医疗管理数据在无登记处的情况下评估乳腺癌筛查性能。

Evaluating breast cancer screening performance without registries using medico-administrative data.

作者信息

Jemelen Emilien, Orchard Francisco, Madie William, Valentin Bernard, Belin Josine, Laas Enora, Jeannerod Guillaume, Mares Pierre, Katsahian Sandrine, Guilloux Agathe

机构信息

French Institute for Research in Computer Science and Automation (INRIA), Paris, France.

Data Science Department, Epiconcept, Paris, France.

出版信息

Sci Rep. 2025 Jul 11;15(1):25096. doi: 10.1038/s41598-025-10115-w.

DOI:10.1038/s41598-025-10115-w
PMID:40646076
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12254203/
Abstract

The French Breast Cancer Screening Program (DOCS) was created to detect early Breast Cancer (BC). Key performance indicators for digital mammography include sensitivity (SE), positive predictive value (PPV), interval cancer rate (ICR) and cancer detection rate (CDR). Calculating these metrics requires a linkage between screening data and BC registries; however, registries are scarce in France and often inaccessible for research. We therefore used medico-administrative data as an alternative. We linked regional screening data to the French National Health Data System (SNDS) between 2011 and 2020. Women were followed for 24 months post-screening. Screen-detected cancers and those identified with the SNDS were included. Performance metrics were calculated based on these linked datasets. A total of 252,786 screening exams were analyzed, covering 29,661-33,447 screenings annually, with a mean age of 61 years. SE was 77.9% (95% CI 76.3-79.3), indicating that approximately four in five cancers were detected through mammography. PPV was 19.8% (95% CI 19-20.5), meaning that one in five women with a positive screening test were confirmed with cancer within 24 months. CDR was 10.9 per 1000 exams (95% CI 10.5-11.3), equating to one detected case per 100 screenings. ICR was 2.4 per 1000 exams (95% CI 2.2-2.6), meaning that more than two interval cancers were detected per 1000 screenings. This identification approach using medico-administrative data offers a reproducible alternative for regions where cancer registries are unavailable. A future study applying this methodology in a registry-covered region could further validate the effectiveness of linking screenings to SNDS data for systematic cancer identification.

摘要

法国乳腺癌筛查项目(DOCS)旨在检测早期乳腺癌(BC)。数字乳腺摄影的关键性能指标包括敏感度(SE)、阳性预测值(PPV)、间期癌发病率(ICR)和癌症检测率(CDR)。计算这些指标需要将筛查数据与乳腺癌登记处相联系;然而,法国的登记处很少,且研究人员通常无法获取。因此,我们使用医疗行政数据作为替代。我们将2011年至2020年期间的区域筛查数据与法国国家卫生数据系统(SNDS)相联系。对女性进行了筛查后24个月的随访。纳入了筛查发现的癌症以及通过SNDS识别出的癌症。基于这些关联数据集计算性能指标。共分析了252,786次筛查检查,每年覆盖29,661 - 33,447次筛查,平均年龄为61岁。敏感度为77.9%(95%置信区间76.3 - 79.3),表明约五分之四的癌症是通过乳腺摄影检测出来的。阳性预测值为19.8%(95%置信区间19 - 20.5),意味着筛查结果呈阳性的女性中,五分之一在24个月内被确诊患有癌症。癌症检测率为每1000次检查10.9例(95%置信区间10.5 - 11.3),相当于每100次筛查发现1例。间期癌发病率为每1000次检查2.4例(95%置信区间2.2 - 2.6),意味着每1000次筛查发现超过2例间期癌。这种使用医疗行政数据的识别方法为没有癌症登记处的地区提供了一种可重复的替代方法。未来在有登记处覆盖的地区应用这种方法的研究可以进一步验证将筛查与SNDS数据相联系以进行系统性癌症识别的有效性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4700/12254203/0dc57e92aa00/41598_2025_10115_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4700/12254203/5466afa203f0/41598_2025_10115_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4700/12254203/553a76efa98f/41598_2025_10115_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4700/12254203/f6e3c65d7e5d/41598_2025_10115_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4700/12254203/0dc57e92aa00/41598_2025_10115_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4700/12254203/5466afa203f0/41598_2025_10115_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4700/12254203/553a76efa98f/41598_2025_10115_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4700/12254203/f6e3c65d7e5d/41598_2025_10115_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4700/12254203/0dc57e92aa00/41598_2025_10115_Fig4_HTML.jpg

相似文献

1
Evaluating breast cancer screening performance without registries using medico-administrative data.使用医疗管理数据在无登记处的情况下评估乳腺癌筛查性能。
Sci Rep. 2025 Jul 11;15(1):25096. doi: 10.1038/s41598-025-10115-w.
2
Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk.乳腺 X 线摄影联合乳腺超声与乳腺 X 线摄影用于一般风险女性乳腺癌筛查。
Cochrane Database Syst Rev. 2023 Mar 31;3(3):CD009632. doi: 10.1002/14651858.CD009632.pub3.
3
The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation.不同原发性乳腺癌治疗后监测性乳房 X 光造影方案的临床效果和成本效益:系统评价注册库分析和经济评估。
Health Technol Assess. 2011 Sep;15(34):v-vi, 1-322. doi: 10.3310/hta15340.
4
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
5
Variation within and between digital pathology and light microscopy for the diagnosis of histopathology slides: blinded crossover comparison study.数字病理学与光学显微镜检查在组织病理学切片诊断中的内部及相互间差异:双盲交叉对比研究
Health Technol Assess. 2025 Jul;29(30):1-75. doi: 10.3310/SPLK4325.
6
Screening for breast cancer: a systematic review update to inform the Canadian Task Force on Preventive Health Care guideline.乳腺癌筛查:为为加拿大预防性医疗保健指南提供信息而进行的系统评价更新
Syst Rev. 2024 Dec 19;13(1):304. doi: 10.1186/s13643-024-02700-3.
7
Full-field digital versus screen-film mammography: comparison within the UK breast screening program and systematic review of published data.全视野数字化乳腺摄影与屏-片乳腺摄影:英国乳腺筛查项目内的比较及已发表数据的系统评价
Radiology. 2009 May;251(2):347-58. doi: 10.1148/radiol.2512081235.
8
Screening for prostate cancer.前列腺癌筛查
Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD004720. doi: 10.1002/14651858.CD004720.pub3.
9
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
10
Clinical symptoms, signs and tests for identification of impending and current water-loss dehydration in older people.老年人即将发生和当前失水脱水的识别的临床症状、体征及检查
Cochrane Database Syst Rev. 2015 Apr 30;2015(4):CD009647. doi: 10.1002/14651858.CD009647.pub2.

本文引用的文献

1
German mammography screening program: program sensitivity between 2010 and 2016 estimated based on German health claims data.德国乳腺 X 光筛查项目:基于德国健康保险索赔数据,估计 2010 年至 2016 年项目灵敏度。
BMC Cancer. 2023 Sep 11;23(1):852. doi: 10.1186/s12885-023-11378-0.
2
A review of the machine learning datasets in mammography, their adherence to the FAIR principles and the outlook for the future.对乳腺 X 线摄影机器学习数据集的回顾,以及它们对 FAIR 原则的遵守情况和未来展望。
Sci Data. 2023 Sep 8;10(1):595. doi: 10.1038/s41597-023-02430-6.
3
Test performance metrics for breast, cervical, colon, and lung cancer screening: a systematic review.
用于乳腺癌、宫颈癌、结肠癌和肺癌筛查的检测性能指标:系统评价。
J Natl Cancer Inst. 2023 Apr 11;115(4):375-384. doi: 10.1093/jnci/djad028.
4
Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studies.20年(2000 - 2020年)间肺癌的趋势及肿瘤特征变化:三项法国连续全国性前瞻性队列研究的结果
Lancet Reg Health Eur. 2022 Aug 29;22:100492. doi: 10.1016/j.lanepe.2022.100492. eCollection 2022 Nov.
5
The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS).法国早期乳腺癌队列研究(FRESH):基于法国国家医疗保健系统数据库(SNDS)的乳腺癌研究及肿瘤学实践评估资源。
Cancers (Basel). 2022 May 27;14(11):2671. doi: 10.3390/cancers14112671.
6
Assessment of a Risk-Based Approach for Triaging Mammography Examinations During Periods of Reduced Capacity.在能力降低期间对乳腺钼靶检查进行基于风险的分流方法的评估。
JAMA Netw Open. 2021 Mar 1;4(3):e211974. doi: 10.1001/jamanetworkopen.2021.1974.
7
Meta-analysis of prospective studies evaluating breast cancer detection and interval cancer rates for digital breast tomosynthesis versus mammography population screening.评估数字乳腺断层合成与乳腺X线摄影人群筛查的乳腺癌检出率和间期癌发生率的前瞻性研究的荟萃分析。
Eur J Cancer. 2021 May;148:14-23. doi: 10.1016/j.ejca.2021.01.035. Epub 2021 Mar 9.
8
Utility of Supplemental Training to Improve Radiologist Performance in Breast Cancer Screening: A Literature Review.补充培训提高放射科医生乳腺癌筛查表现的效用:文献综述。
J Am Coll Radiol. 2019 Nov;16(11):1528-1546. doi: 10.1016/j.jacr.2019.04.016. Epub 2019 Jun 24.
9
Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France.国家行政数据库对指导公共决策的价值:从法国的全国疾病保险跨制度信息系统(SNIIRAM)到全国健康数据系统(SNDS)
Rev Epidemiol Sante Publique. 2017 Oct;65 Suppl 4:S149-S167. doi: 10.1016/j.respe.2017.05.004. Epub 2017 Jul 27.
10
[Determination of interval cancer rates in the German mammography screening program using population-based cancer registry data].[利用基于人群的癌症登记数据确定德国乳腺X线筛查项目中的间期癌发病率]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Jan;57(1):68-76. doi: 10.1007/s00103-013-1883-2.